Skip to main content

Table 3 Percentage of compliance of trial records according to WHO criteria by trial registry.

From: Compliance of clinical trial registries with the World Health Organization minimum data set: a survey

  Registries (number of records)
  International National Specialty Pharma   
Criteria requested ISCRTN (n = 100) CT (n = 100) ACTR (n = 50) UK NRR (n = 50) PDQ (n = 33) STD (n = 33) RT (n = 33) R (n = 8) GSK (n = 72) N (n = 4) CSR (n = 37) Local (n = 90) Total, % (95% CI)
   Unique trial number 100 100 100 100 0 0 0 100 100 100 97.3 90 82.1 (78.9 to 85.1)
   Trial registration date 100 100 100 100 100 100 100 100 100 0 0 0 78.5 (75.0 to 81.7)
   Secondary Ids 100 91 16 4 100 0 0 0 0 0 0 0 38.4 (34.5 to 42.4)
   Funding source(s) 100 100 96 76 66.7 69.7 90 100 100 100 100 27.8 83.1 (79.9 to 86.0)
   Primary sponsor 100 100 90 92 66.7 69.7 90.9 100 31.9 100 100 27.8 75.9 (72.3 to 79.2)
   Secondary sponsor(s) 14 10 38 0 0 6.1 6.1 0 0 0 0 0 7.7 (5.7 to 10.1)
   Responsible contact person 0 0 100 0 0 0 0 0 0 0 0 0 8.2 (6.1 to 10.7)
   Research contact person 95 20 100 98 93.9 63.6 30.3 0 0 0 0 60 54.1 (50.1 to 58.1)
   Title of the study (brief title) 98 18 66 0 0 60.6 0 0 0 0 0 12.2 29.5 (25.9 to 33.3)
   Official scientific title of the study 83 95 100 94 97 69.7 84.9 100 100 0 89.2 82.2 89.3 (86.6 to 91.7)
   Research ethics review 1 0 78 0 3 0 3 0 0 0 0 0 6.9 (5.0 to 9.2)
   Condition 70 85 92 66 97 100 84.9 100 95.8 100 83.8 22.2 75.2 (71.6 to 78.6)
   Intervention(s) 56 68 74 24 75.8 97 42.4 0 100 0 64.9 17.8 58.4 (54.3 to 62.3)
   Key inclusion and exclusion criteria 23 97 100 44 18.2 87.9 0 100 97.2 50 64.9 28.9 58.5 (54.5 to 62.5)
   Study type 43 74 98 58 9.1 97 33.3 0 94.4 0 64.9 45.6 61.3 (57.3 to 65.2)
   Anticipated trial start date 8 65 100 100 0 39.4 3 0 100 0 64.9 0 46.4 (42.4 to 50.4)
   Target sample size 40 83 100 24 72.7 100 39.4 0 80.6 0 64.9 0 55.2 (51.2 to 59.2)
   Recruitment status 3 99 100 100 93.9 100 12.1 100 0 0 54.1 7.8 50.0 (46.0 to 54.0)
   Primary outcome 7 48 100 34 0 100 18.2 0 83.3 0 64.9 2.2 40.5 (36.6 to 44.5)
   Key secondary outcomes 6 10 58 6 6.1 54.6 3 0 61.1 0 48.7 1.1 21.6 (18.4 to 25.1)
  1. Note: In CT, PDQ and STD 'Funding source(s)' and 'Primary sponsor' are not distinct. By default contact person without specification has been refereed to Research contact person.
  2. Abbreviation: ISRCTN, Current Controlled Trials; CT, ClinicalTrials.gov; ACTR, Australian Clinical Trials Registry; UK NRR, UK National Research Register; PDQ, US National Cancer Institute; STD, Stroke Trials Directory; RT, Rehabilitation Trials; R, Roche; GSK, GlaxoSmithKline; N, Novartis; CSR, ClinicalStudyResults.